Daclatasvir TRIO regimen has good cure rates for hepatitis C patients with or without cirrhosis
Sofosbuvir/ledipasvir cures nearly all genotype 1 HCV for people with HIV co-infection
AbbVie 3D HCV regimen well-tolerated in PEARL trials
Sofosbuvir/ledipasvir safe and effective for genotype 1 HCV
Low uptake of HCV treatment in England will lead to substantial disease burden by 2035
Sofosbuvir + ribavirin is safe and effective for HCV recurrence after liver transplantation
Three-drug AbbVie combination safe and highly effective in treatment of post-transplant hepatitis C recurrence
Sofosbuvir + new GS-5816 NS5A inhibitor is effective against hepatitis C genotypes 1-6
